Ravidasvir

Ravidasvir
Clinical data
Other names	PPI-668
ATC code	None;
Identifiers
	show IUPAC name
CAS Number	1242087-93-9;
PubChem CID	52918888;
ChemSpider	31141686;
UNII	AL3G001BI8;
ChEMBL	ChEMBL3121849;
Chemical and physical data
Formula	C42H50N8O6
Molar mass	762.912 g·mol−1
3D model (JSmol)	Interactive image;
	show SMILES
	show InChI

Ravidasvir (PPI-668) is an investigational NS5A inhibitor (by ) in clinical trials for chronic hepatitis C genotype 4.^[1]

Preliminary clinical trial results were announced in Nov 2015.^[2] In April 2017, press reports stated that a combination treatment involving ravidasvir and sofosbuvir had achieved a 97% clearup rate against hepatitis C in a clinical trial conducted in Malaysia and Thailand, and 100% in another conducted in Egypt.^[3] It has been granted conditional registration by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia.^[4]^[5]

References[]

^ Clinical trial number NCT02371408 for "Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4" at ClinicalTrials.gov
^ "Good Results for Sovaldi and Ravidasvir Treating Hepatitis C Genotype 4". Hepatitis Magazine. 24 November 2015.
^ Kollewe J (13 April 2018). "Non-profit's $300 hepatitis C cure as effective as $84,000 alternative". The Guardian.
^ "List of new products approved by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia" (PDF).
^ "First hepatitis C treatment developed through South-South cooperation registered in Malaysia | DNDi". dndi.org. 14 June 2021. Retrieved 10 August 2021.

This antiinfective drug article is a stub. You can help Wikipedia by .

[1] Clinical trial number NCT02371408 for "Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4" at ClinicalTrials.gov

[2] "Good Results for Sovaldi and Ravidasvir Treating Hepatitis C Genotype 4". Hepatitis Magazine. 24 November 2015.

[3] Kollewe J (13 April 2018). "Non-profit's $300 hepatitis C cure as effective as $84,000 alternative". The Guardian.

[4] "List of new products approved by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia" (PDF).

[5] "First hepatitis C treatment developed through South-South cooperation registered in Malaysia | DNDi". dndi.org. 14 June 2021. Retrieved 10 August 2021.

[1]

[2]

[3]

[4]

[5]

Ravidasvir

See also[]

References[]